Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors

Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors

Vasohibin‐1 (VASH1) is a negative feedback regulator of angiogenesis, the first to be discovered, and was identified in vascular endothelial growth factor (VEGF)‐stimulated vascular endothelial cells. Vasohibin‐1 inhibits abnormal vascularization induced by various angiogenic factors including fibro...

Full description

Bibliographic Details
Main Authors: Takahashi, Yoshifumi, Saga, Yasushi, Koyanagi, Takahiro, Takei, Yuji, Machida, Shizuo, Taneichi, Akiyo, Mizukami, Hiroaki, Sato, Yasufumi, Matsubara, Shigeki, Fujiwara, Hiroyuki
Format: Online
Language:English
Published: John Wiley and Sons Inc. 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970829/
id pubmed-4970829
recordtype oai_dc
spelling pubmed-49708292016-08-11 Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors Takahashi, Yoshifumi Saga, Yasushi Koyanagi, Takahiro Takei, Yuji Machida, Shizuo Taneichi, Akiyo Mizukami, Hiroaki Sato, Yasufumi Matsubara, Shigeki Fujiwara, Hiroyuki Original Articles Vasohibin‐1 (VASH1) is a negative feedback regulator of angiogenesis, the first to be discovered, and was identified in vascular endothelial growth factor (VEGF)‐stimulated vascular endothelial cells. Vasohibin‐1 inhibits abnormal vascularization induced by various angiogenic factors including fibroblast growth factor and platelet‐derived growth factor (PDGF), in addition to VEGF. By focusing on this characteristic of VASH1, we investigated the antitumor effects of VASH1 expression on ovarian cancer cells that produce different angiogenic factors. By using a high VEGF‐producing ovarian cancer cell line, SHIN‐3, and a high PDGF‐producing ovarian cancer cell line, KOC‐2S, the cells were transfected with either a VEGF antagonist, soluble VEGF receptor‐1 (sVEGFR‐1, or sFlt‐1), or VASH1 genes to establish their respective cellular expression. The characteristics of these transfectants were compared with controls. We previously reported that the expression of sFlt‐1 inhibited tumor vascularization and growth of high VEGF‐producing ovarian cancer cells, reduced peritoneal dissemination and ascites development, and prolonged the survival time of the host. However, in the current study, the expression of sFlt‐1 had no such effect on the high PDGF‐producing ovarian cancer cells used here, whereas VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF‐producing cells, but also in high PDGF‐producing cells, reduced their peritoneal dissemination and ascites, and prolonged the survival time of the host. These results suggest that VASH1 is an effective treatment for ovarian cancer cells that produce different angiogenic factors. John Wiley and Sons Inc. 2016-03-30 2016-05 /pmc/articles/PMC4970829/ /pubmed/26893100 http://dx.doi.org/10.1111/cas.12911 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Takahashi, Yoshifumi
Saga, Yasushi
Koyanagi, Takahiro
Takei, Yuji
Machida, Shizuo
Taneichi, Akiyo
Mizukami, Hiroaki
Sato, Yasufumi
Matsubara, Shigeki
Fujiwara, Hiroyuki
spellingShingle Takahashi, Yoshifumi
Saga, Yasushi
Koyanagi, Takahiro
Takei, Yuji
Machida, Shizuo
Taneichi, Akiyo
Mizukami, Hiroaki
Sato, Yasufumi
Matsubara, Shigeki
Fujiwara, Hiroyuki
Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
author_facet Takahashi, Yoshifumi
Saga, Yasushi
Koyanagi, Takahiro
Takei, Yuji
Machida, Shizuo
Taneichi, Akiyo
Mizukami, Hiroaki
Sato, Yasufumi
Matsubara, Shigeki
Fujiwara, Hiroyuki
author_sort Takahashi, Yoshifumi
title Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
title_short Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
title_full Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
title_fullStr Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
title_full_unstemmed Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
title_sort vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors
description Vasohibin‐1 (VASH1) is a negative feedback regulator of angiogenesis, the first to be discovered, and was identified in vascular endothelial growth factor (VEGF)‐stimulated vascular endothelial cells. Vasohibin‐1 inhibits abnormal vascularization induced by various angiogenic factors including fibroblast growth factor and platelet‐derived growth factor (PDGF), in addition to VEGF. By focusing on this characteristic of VASH1, we investigated the antitumor effects of VASH1 expression on ovarian cancer cells that produce different angiogenic factors. By using a high VEGF‐producing ovarian cancer cell line, SHIN‐3, and a high PDGF‐producing ovarian cancer cell line, KOC‐2S, the cells were transfected with either a VEGF antagonist, soluble VEGF receptor‐1 (sVEGFR‐1, or sFlt‐1), or VASH1 genes to establish their respective cellular expression. The characteristics of these transfectants were compared with controls. We previously reported that the expression of sFlt‐1 inhibited tumor vascularization and growth of high VEGF‐producing ovarian cancer cells, reduced peritoneal dissemination and ascites development, and prolonged the survival time of the host. However, in the current study, the expression of sFlt‐1 had no such effect on the high PDGF‐producing ovarian cancer cells used here, whereas VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF‐producing cells, but also in high PDGF‐producing cells, reduced their peritoneal dissemination and ascites, and prolonged the survival time of the host. These results suggest that VASH1 is an effective treatment for ovarian cancer cells that produce different angiogenic factors.
publisher John Wiley and Sons Inc.
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970829/
_version_ 1613619986275762176

Similar Items